{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:34:40Z","timestamp":1792290880740,"version":"4.4.0"},"reference-count":119,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T00:00:00Z","timestamp":1596067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The lytic bone disease is a hallmark of multiple myeloma, being present in about 80% of patients with newly diagnosed MM, and in more during the disease course. The myeloma associated bone disease (MBD) severely affects the morbidity and quality of life of the patients. MBD defines treatment demanding MM. In recent years, knowledge of the underlying pathophysiology has increased, and novel imaging technologies, medical and non-pharmaceutical treatments have improved. In this review, we highlight the major achievements in understanding, diagnosing and treating MBD. For diagnosing MBD, low-dose whole-body CT is now recommended over conventional skeletal survey, but also more advanced functional imaging modalities, such as diffusion-weighted MRI and PET\/CT are increasingly important in the assessment and monitoring of MBD. Bisphosphonates have, for many years, played a key role in management of MBD, but denosumab is now an alternative to bisphosphonates, especially in patients with renal impairment. Radiotherapy is used for uncontrolled pain, for impeding fractures and in treatment of impeding or symptomatic spinal cord compression. Cement augmentation has been shown to reduce pain from vertebral compression fractures. Cautious exercise programs are safe and feasible and may have the potential to improve the status of patients with MM.<\/jats:p>","DOI":"10.3390\/cancers12082113","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T12:15:38Z","timestamp":1596111338000},"page":"2113","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Multiple Myeloma Associated Bone Disease"],"prefix":"10.3390","volume":"12","author":[{"given":"Stine","family":"Rasch","sequence":"first","affiliation":[{"name":"Department of Haematology, Odense University Hospital, Kloevervaenget 10, 12th Floor, DK-5000 Odense, Denmark"},{"name":"Department of Internal Medicine, Division of Haematology, Sydvestjysk Sygehus, Finsensgade 35, DK-6700 Esbjerg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lund","sequence":"additional","affiliation":[{"name":"Department of Haematology, Odense University Hospital, Kloevervaenget 10, 12th Floor, DK-5000 Odense, Denmark"},{"name":"Haematology Research Unit, Department of Clinical Research, University of Southern Denmark, Kloevervaenget 10, 12th Floor, DK-5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon Thor","family":"Asmussen","sequence":"additional","affiliation":[{"name":"Department of Clinical Radiology, Odense University Hospital, Sdr. Boulevard 29, DK-5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Lerberg Nielsen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Odense University Hospital, Sdr. Boulevard 29, DK-5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke","family":"Faebo Larsen","sequence":"additional","affiliation":[{"name":"Department of Haematology, Odense University Hospital, Kloevervaenget 10, 12th Floor, DK-5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8478-8218","authenticated-orcid":false,"given":"Mikkel","family":"\u00d8sterheden Andersen","sequence":"additional","affiliation":[{"name":"Center for Spine Surgery &amp; Research, Lillebaelt Hospital, \u00d8stre Hougvel 55, DK-5500 Middelfart, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Abildgaard","sequence":"additional","affiliation":[{"name":"Department of Haematology, Odense University Hospital, Kloevervaenget 10, 12th Floor, DK-5000 Odense, Denmark"},{"name":"Haematology Research Unit, Department of Clinical Research, University of Southern Denmark, Kloevervaenget 10, 12th Floor, DK-5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","article-title":"Multiple myeloma","volume":"374","author":"Raab","year":"2009","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1055\/s-0030-1248705","article-title":"The Role of Whole-Body Imaging in the Diagnosis, Staging, and Follow-Up of Multiple Myeloma","volume":"14","author":"Shortt","year":"2010","journal-title":"Semin. Musculoskelet. Radiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma","volume":"43","author":"Cocks","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00520-013-1991-4","article-title":"Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: Results of a European, multicenter cohort study","volume":"22","author":"Jordan","year":"2014","journal-title":"Support. Care Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/leu.2010.62","article-title":"Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease","volume":"24","author":"Terpos","year":"2010","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002\u2014Medical Research Council Adult Leukaemia Working Party","volume":"23","author":"Augustson","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13045-016-0282-1","article-title":"Novel agents in the treatment of multiple myeloma: A review about the future","volume":"9","author":"Naymagon","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/joim.12590","article-title":"Modern multiple myeloma therapy: Deep, sustained treatment response and good clinical outcomes","volume":"281","author":"Landgren","year":"2017","journal-title":"J. Intern. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Vallet, S., Filzmoser, J.-M., Pecherstorfer, M., and Podar, K. (2018). Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10040202"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000351895","article-title":"Cellular and Molecular Aspects of Bone Remodeling","volume":"18","author":"Xiao","year":"2016","journal-title":"Front. Oral. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","article-title":"Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition","volume":"108","author":"Giuliani","year":"2006","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41413-018-0019-6","article-title":"Paracrine and endocrine actions of bone-the functions of secretory proteins from osteoblasts, osteocytes, and osteoclasts","volume":"6","author":"Han","year":"2018","journal-title":"Bone Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: Proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/1759720X12466608","article-title":"Wnt signaling in bone formation and its therapeutic potential for bone diseases","volume":"5","author":"Kim","year":"2013","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1182\/blood-2008-01-132134","article-title":"Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: A potential mechanism underlying osteolytic bone lesions in multiple myeloma","volume":"112","author":"Qiang","year":"2008","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3109\/10428194.2013.820288","article-title":"Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: Only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease","volume":"55","author":"Kristensen","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/leu.2015.259","article-title":"Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20","volume":"30","author":"Palma","year":"2016","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2141.2009.07980.x","article-title":"Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells","volume":"148","author":"Andersen","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"100646","DOI":"10.1016\/j.blre.2019.100646","article-title":"Why do myeloma patients have bone disease? A historical perspective","volume":"41","author":"Sundan","year":"2020","journal-title":"Blood Rev."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"(2003). Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br. J. Haematol., 121, 749\u2013757.","DOI":"10.1046\/j.1365-2141.2003.04355.x"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13045-017-0549-1","article-title":"Diagnosis, treatment, and response assessment in solitary plasmacytoma: Updated recommendations from a European Expert Panel","volume":"11","author":"Caers","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.blre.2019.04.002","article-title":"Extramedullary disease in multiple myeloma-controversies and future directions","volume":"36","author":"Sevcikova","year":"2019","journal-title":"Blood Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/leu.2009.89","article-title":"International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0009-9260(67)80010-2","article-title":"The radiological demonstration of osseous metastases. Experimental observations","volume":"18","author":"Edelstyn","year":"1967","journal-title":"Clin. Radiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.3324\/haematol.2016.146092","article-title":"Baseline bone involvement in multiple myeloma\u2014A prospectiv prospective comparison of conventional X-ray, low-dose computed tomography, and 18flourodeoxyglucose positron emission tomography in previously untreated patients","volume":"101","author":"Hinge","year":"2016","journal-title":"Haematologica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e599","DOI":"10.1038\/bcj.2017.78","article-title":"Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: A study of the International Myeloma Working Group","volume":"7","author":"Hillengass","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/bloodadvances.2017014720","article-title":"Prognostic significance of bone marrow abnormalities in the appendicular skeleton of patients with multiple myeloma","volume":"2","author":"Matsue","year":"2018","journal-title":"Blood Adv."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.V90.6.2127","article-title":"Magnetic Resonance Imaging of the Bone Marrow in Hematologic Malignancies","volume":"90","author":"Moulopoulos","year":"1997","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.ejrad.2014.02.008","article-title":"Sensitivity of whole-body CT and MRI versus projection radiography in the detection of osteolyses in patients with monoclonal plasma cell disease","volume":"83","author":"Wolf","year":"2014","journal-title":"Eur. J. Radiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1200\/JCO.2006.08.5803","article-title":"Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications","volume":"25","author":"Walker","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2214\/AJR.07.2635","article-title":"Whole-Body MRI Versus Whole-Body MDCT for Staging of Multiple Myeloma","volume":"190","author":"Buhmann","year":"2008","journal-title":"Am. J. Roentgenol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1055\/s-2001-12920","article-title":"Magnetic resonance and computed tomography imaging in multiple myeloma","volume":"5","author":"Lecouvet","year":"2001","journal-title":"Semin. Musculoskelet. Radiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/leu.2014.230","article-title":"The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma","volume":"28","author":"Kastritis","year":"2014","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/leu.2014.75","article-title":"Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma","volume":"28","author":"Merz","year":"2014","journal-title":"Leukemia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ijlh.12581","article-title":"Review of the NICE guidelines for multiple myeloma","volume":"39","author":"Pratt","year":"2017","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_43","unstructured":"(2020, March 04). 1 Guidance|Metastatic Spinal Cord Compression in Adults: Risk Assessment, Diagnosis and Management|Guidance|NICE. Available online: https:\/\/www.nice.org.uk\/guidance\/CG75\/chapter\/1-Guidance#imaging."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.3174\/ajnr.A5528","article-title":"Review of the Imaging Features of Benign Osteoporotic and Malignant Vertebral Compression Fractures","volume":"39","author":"Mauch","year":"2018","journal-title":"Am. J. Neuroradiol."},{"key":"ref_45","unstructured":"(2020, March 05). Role of 18 F-FDG PET\/CT in the Diagnosis and Management of Multiple Myeloma and Other Plasma Cell Disorders: A Consensus Statement by the International Myeloma Working Group-Clinical Key. Available online: https:\/\/www-clinicalkey-com.proxy2-bib.sdu.dk\/#!\/content\/journal\/1-s2.0-S1470204517301894."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3324\/haematol.10554","article-title":"A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma","volume":"92","author":"Zamagni","year":"2007","journal-title":"Haematologica"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.critrevonc.2018.02.012","article-title":"Comparison of whole body magnetic resonance imaging (WBMRI) to whole body computed tomography (WBCT) or 18F-fluorodeoxyglucose positron emission tomography\/CT (18F-FDG PET\/CT) in patients with myeloma: Systematic review of diagnostic performance","volume":"124","author":"Gariani","year":"2018","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1182\/blood-2012-08-451690","article-title":"Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3","volume":"121","author":"Usmani","year":"2013","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3348\/kjr.2018.19.3.481","article-title":"Prognostic Value of Baseline 18F-Fluorodeoxyglucose PET\/CT in Patients with Multiple Myeloma: A Multicenter Cohort Study","volume":"19","author":"Moon","year":"2018","journal-title":"Korean J. Radiol."},{"key":"ref_52","first-page":"332","article-title":"Fluorine-18: A new isotope for bone scanning","volume":"3","author":"Blau","year":"1962","journal-title":"J. Nucl. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2967\/jnumed.106.037200","article-title":"Skeletal PET with 18F-Fluoride: Applying New Technology to an Old Tracer","volume":"49","author":"Grant","year":"2008","journal-title":"J. Nucl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1053\/j.semnuclmed.2007.07.002","article-title":"18F-Fluoride Positron Emission Tomography and Positron Emission Tomography\/Computed Tomography","volume":"37","author":"Mishani","year":"2007","journal-title":"Semin. Nucl. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12149-012-0647-7","article-title":"Role of 18F-fluoride PET\/CT in the assessment of multiple myeloma: Initial experience","volume":"27","author":"Nishiyama","year":"2013","journal-title":"Ann. Nucl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00259-014-2721-y","article-title":"PET\/CT studies of multiple myeloma using (18)\u2009F-FDG and (18)\u2009F-NaF: Comparison of distribution patterns and tracers\u2019 pharmacokinetics","volume":"41","author":"Sachpekidis","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00277-015-2410-3","article-title":"Is there any complimentary role of F-18 NaF PET\/CT in detecting of osseous involvement of multiple myeloma? A comparative study for F-18 FDG PET\/CT and F-18 FDG NaF PET\/CT","volume":"94","author":"Ak","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00259-016-3502-6","article-title":"Treatment response evaluation with 18F-FDG PET\/CT and 18F-NaF PET\/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation","volume":"44","author":"Sachpekidis","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_59","first-page":"110","article-title":"Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer","volume":"61","author":"DeGrado","year":"2001","journal-title":"Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0969-8051(00)00195-5","article-title":"Characterization of acetate metabolism in tumor cells in relation to cell proliferation: Acetate metabolism in tumor cells","volume":"28","author":"Yoshimoto","year":"2001","journal-title":"Nucl. Med. Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1477-7819-5-68","article-title":"11C-choline vs. 18F-FDG PET\/CT in assessing bone involvement in patients with multiple myeloma","volume":"5","author":"Nanni","year":"2007","journal-title":"World J. Surg. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s00259-016-3392-7","article-title":"18F-fluorocholine versus 18F-fluorodeoxyglucose for PET\/CT imaging in patients with suspected relapsing or progressive multiple myeloma: A pilot study","volume":"43","author":"Balogova","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","article-title":"Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM\/DFCI 2009 Trial: Results of the IMAJEM Study","volume":"35","author":"Moreau","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/leu.2015.338","article-title":"Whole-body diffusion-weighted MRI: A new gold standard for assessing disease burden in patients with multiple myeloma?","volume":"30","author":"Pawlyn","year":"2016","journal-title":"Leukemia"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_66","first-page":"2","article-title":"Mechanisms of action of bisphosphonates in oncology: A scientific concept evolving from antiresorptive to anticancer activities","volume":"2","year":"2013","journal-title":"Bonekey Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(11)70157-7","article-title":"Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): Secondary outcomes from a randomised controlled trial","volume":"12","author":"Morgan","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_70","first-page":"CD003188","article-title":"Bisphosphonates in multiple myeloma: An updated network meta-analysis","volume":"12","author":"Mhaskar","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3109\/10428194.2014.924117","article-title":"Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma","volume":"56","author":"Sanfilippo","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3109\/10428194.2011.553000","article-title":"Pamidronate versus observation in asymptomatic myeloma: Final results with long-term follow-up of a randomized study","volume":"52","author":"Gobbi","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/cncr.23783","article-title":"A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma","volume":"113","author":"Musto","year":"2008","journal-title":"Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1182\/blood-2011-11-392522","article-title":"Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: The Medical Research Council Myeloma IX Trial","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/bjh.12861","article-title":"Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results","volume":"166","author":"Jackson","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.clml.2017.02.007","article-title":"Prolonged Use of Zoledronic Acid (4 Years) Did Not Improve Outcome in Multiple Myeloma Patients","volume":"17","author":"Aviles","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"516","DOI":"10.4065\/82.4.516","article-title":"Use of Bisphosphonates in Multiple Myeloma: IMWG Response to Mayo Clinic Consensus Statement","volume":"82","author":"Durie","year":"2007","journal-title":"Mayo Clin. Proc."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1182\/blood-2013-04-498139","article-title":"The impact of response on bone-directed therapy in patients with multiple myeloma","volume":"122","author":"Larocca","year":"2013","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1158\/1078-0432.CCR-15-1864","article-title":"Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study","volume":"22","author":"Raje","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3324\/haematol.2015.128439","article-title":"Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: Results of the randomized AZABACHE Spanish trial","volume":"100","author":"Oriol","year":"2015","journal-title":"Haematologica"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: An international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_84","unstructured":"(2020, March 23). Identification of Risk Factors for Bisphosphonate-Associated Atypical Femoral Fractures and Osteonecrosis of the Jaw in a Pharmacovigilance Database-Rebecca S. Bejhed, Mohammad Kharazmi, P\u00e4r Hallberg. Available online: https:\/\/journals-sagepub-com.proxy1-bib.sdu.dk\/doi\/10.1177\/1060028016649368."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1359\/jbmr.1997.12.10.1700","article-title":"Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis","volume":"12","author":"Khan","year":"1997","journal-title":"J. Bone Miner. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: A review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","journal-title":"Bone"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1080\/10428190802483778","article-title":"Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates","volume":"49","author":"Montefusco","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Mateos, M.-V., Fink, L., Koneswaran, N., Intorcia, M., Giannopoulou, C., Niepel, D., and Cavo, M. (2020). Bone complications in patients with multiple myeloma in five European countries: A retrospective patient chart review. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-6596-y"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: Different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood-2019-127290","article-title":"Progression-Free Survival Analysis of Denosumab Vs Zoledronic Acid in Intent to Transplant Multiple Myeloma Patients Based on Treatment Regimen and Baseline Characteristics","volume":"134","author":"Terpos","year":"2019","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"8983","DOI":"10.1038\/ncomms9983","article-title":"Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche","volume":"6","author":"Lawson","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s00520-014-2521-8","article-title":"Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency","volume":"23","author":"Watkins","year":"2015","journal-title":"Support. Care Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass","volume":"96","author":"Bone","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/jbmr.2490","article-title":"OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice","volume":"30","author":"Shimamoto","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11914-019-00502-4","article-title":"Stopping Denosumab","volume":"17","author":"Lamy","year":"2019","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"key":"ref_98","first-page":"40","article-title":"Current Role of Radiation Therapy for Multiple Myeloma","volume":"5","author":"eTalamo","year":"2015","journal-title":"Front. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1515\/raon-2016-0029","article-title":"Excellent outcomes after radiotherapy alone for malignant spinal cord compression from myeloma","volume":"50","author":"Rades","year":"2016","journal-title":"Radiol. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.clml.2014.07.010","article-title":"Feasibility and Efficacy of Local Radiotherapy With Concurrent Novel Agents in Patients With Multiple Myeloma","volume":"14","author":"Shin","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1470-2045(11)70008-0","article-title":"Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: A multicentre, randomised controlled trial","volume":"12","author":"Berenson","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/BSD.0b013e318260a076","article-title":"Functional Outcomes and Height Restoration for Patients with Multiple Myeloma-Related Osteolytic Vertebral Compression Fractures Treated with Kyphoplasty","volume":"27","author":"Julka","year":"2014","journal-title":"J. Spinal Disord. Tech."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3174\/ajnr.A3622","article-title":"Vertebral Augmentation in Patients with Multiple Myeloma: A Pooled Analysis of Published Case Series","volume":"35","author":"Khan","year":"2014","journal-title":"Am. J. Neuroradiol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jpain.2012.03.003","article-title":"Changes in pain and other symptoms in patients with painful multiple myeloma-related vertebral fracture treated with kyphoplasty or vertebroplasty","volume":"13","author":"Mendoza","year":"2012","journal-title":"J. Pain"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Malhotra, K., Butler, J.S., Yu, H.M., Selvadurai, S., D\u2019Sa, S., Rabin, N., Kyriakou, C., Yong, K., and Molloy, S. (2016). Spinal disease in myeloma: Cohort analysis at a specialist spinal surgery centre indicates benefit of early surgical augmentation or bracing. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2495-7"},{"key":"ref_107","first-page":"A4945","article-title":"Pain reduction after percutaneous vertebroplasty for myeloma-associated vertebral fractures","volume":"61","author":"Simony","year":"2014","journal-title":"Dan. Med. J."},{"key":"ref_108","unstructured":"Health Quality Ontario (2016). Vertebral Augmentation Involving Vertebroplasty or Kyphoplasty for Cancer-Related Vertebral Compression Fractures: A Systematic Review. Ont. Health Technol. Assess. Ser., 16, 1\u2013202."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/ecc.12158","article-title":"Early application of percutaneous vertebroplasty reduces pain without affecting peripheral blood stem cell (PBSC) collection and transplant in newly diagnosed multiple myeloma (MM) patients","volume":"23","author":"Tosi","year":"2014","journal-title":"Eur. J. Cancer Care"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41408-019-0187-7","article-title":"The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: A consensus statement from the International Myeloma Working Group (IMWG)","volume":"9","author":"Kyriakou","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"Br. Med. J."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s00586-020-06392-w","article-title":"Percutaneous vertebroplasty as treatment of malignant vertebral lesions: A systematic review and GRADE evaluation resulting in a Danish national clinical guideline","volume":"29","author":"Rousing","year":"2020","journal-title":"Eur. Spine J."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/bjsports-2017-097891","article-title":"Which exercise prescriptions improve quality of life and physical function in patients with cancer during and following treatment? A systematic review and meta-analysis of randomised controlled trials","volume":"52","author":"Sweegers","year":"2018","journal-title":"Br. J. Sports Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1249\/MSS.0000000000002116","article-title":"Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable","volume":"51","author":"Campbell","year":"2019","journal-title":"Med. Sci. Sports Exerc."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e009576","DOI":"10.1136\/bmjopen-2015-009576","article-title":"Multiple myeloma and physical activity: A scoping review","volume":"5","author":"Smith","year":"2015","journal-title":"BMJ Open"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.critrevonc.2015.11.005","article-title":"The effectiveness of exercise programmes in patients with multiple myeloma: A literature review","volume":"98","author":"Gan","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Larsen, R.F., Jarden, M., Minet, L.R., Fr\u00f8lund, U.C., M\u00f6ller, S., and Abildgaard, N. (2020). Physical function in patients newly diagnosed with multiple myeloma; a Danish cohort study. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-6637-6"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s40814-019-0518-2","article-title":"Supervised and home-based physical exercise in patients newly diagnosed with multiple myeloma\u2014A randomized controlled feasibility study","volume":"5","author":"Larsen","year":"2019","journal-title":"Pilot Feasibil. Stud."},{"key":"ref_119","unstructured":"Larsen, R.F., Jaden, M., Minet, L.R., Fr\u00f8lund, U.C., M\u00f6ller, S., and Abildgaard, N. (2020, June 12). Exercise in Newly Diagnosed Patients with Multiple Myeloma\u2014A Randomized, Controlled Trial of Effects on Physical Function, Physical Activity. European Haematology Association (EHA) Congress 2020. Available online: https:\/\/library.ehaweb.org\/eha\/2020\/eha25th\/294240\/rikke.faebo.larsen.exercise.in.newly.diagnosed.patients.with.multiple.myeloma.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dep1760."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/8\/2113\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:52:51Z","timestamp":1760176371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/8\/2113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,30]]},"references-count":119,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["cancers12082113"],"URL":"https:\/\/doi.org\/10.3390\/cancers12082113","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202007.0041.v1","asserted-by":"object"}]},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,30]]}}}